NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
OCTREOSCAN (indium in -111 pentetreotide) by Curium Pharma is clinical pharmacology general pentetreotide is a dtpa conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. First approved in 1994.
Drug data last refreshed Just now · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCTREOSCAN is an indium-111 radiolabeled diagnostic imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells. It localizes to somatostatin receptor-rich tumors and normal tissues including pituitary, thyroid, liver, and spleen, enabling visualization and detection of neuroendocrine malignancies. The drug works through rapid plasma clearance and renal excretion, with peak tumor uptake achievable within hours post-injection.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% rating); commercial team likely consolidating to support managed decline and transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY General Pentetreotide is a DTPA conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. Indium In 111 pentetreotide binds to somatostatin receptors on cell surfaces throughout the body. Within an hour of injection, most of the dose of indium…
Worked on OCTREOSCAN at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.